KRAS and colorectal carcinoma: To determine mechanisms of action and inform on pharmacodynamic markers of response, we performed reverse phase protein arrays (RPPA) using protein lysates obtained from 10 KRAS mutant CRC cell lines treated for 24 hours with MEK162, palbociclib, the combination, or DMSO control (Figure 4A–4B).